Key Takeaways:
An investigation into TriSalus Life Sciences Inc. (TLSI) for possible securities fraud was announced by several law firms after the company’s stock price fell 41.56% following a significant cut to its full-year revenue guidance.
The company attributed the lowered forecast to disappointing first-quarter sales and a prolonged delay in regulatory clearance for a key medical device. Management stated on an earnings call that "the driver of this revision includes both the lower Q1 revenues from the commercial expansion and the delayed FDA clearance timing for TriNav Advance."
On May 12, TriSalus slashed its 2026 revenue outlook to a range of $54 million to $57 million. The revision came just over two months after CEO Mary Szela had reaffirmed prior guidance of $60 million to $62 million on a March 5 earnings call. The company also reported Q1 revenue of $8.9 million, missing consensus estimates, and disclosed that FDA clearance for its TriNav Advance device was running approximately five months behind schedule.
The news prompted a sharp selloff, with TriSalus shares falling $1.89 to close at $2.67 on May 13, injuring investors. The announced investigations are examining whether the company and its executives made materially false or misleading statements regarding its business outlook and operational timelines.
The guidance cut represented a $5.5 million reduction at the midpoint compared to the forecast the company had supported just weeks earlier. On the March 5 call, CEO Mary Szela had told investors that the company's expected performance "should not be interpreted as a change in underlying demand trends." Law firms are now calling for investors who suffered losses on the stock to inquire about pursuing claims to recover damages.
The stock's sharp decline brings its price to the lowest levels since its public listing. Investors will be closely watching for outcomes from the securities fraud investigations and any further updates on the delayed FDA clearance for the TriNav Advance device.
This article is for informational purposes only and does not constitute investment advice.
